Ana Weaver
Currently, over 185 million individuals have been infected globally with COVID-19 and researchers predict that it will take months before we have medications to treat or heal the virus efficiently.
Maybe it was not strange if cannabidiol (CBD) advertising were to arise amid the outbreak of COVID-19. And besides, its antiviral capabilities have shown the cannabis component in the last several years. However, this does not indicate the new coronavirus is effective. And it may not be safe for those taking certain medicines.
A number of CBD and cannabis literature were written as possible COVID-19 therapies. It is crucial to note that cannabinoids can either aid or damage a patient depending on the stage of the disease; as each phase of the disease probably needs a wide range of treatment. In the early phases, patients have to respond immune to fighting the virus in order to achieve the greatest possible immune system. However, in the future when a patient with a severely affected COVID-19 develops a cytokine storm, it might be utilized to counter its detrimental, often deadly, consequences through the immunosuppressive action of cannabis.
Cannabis in COVID-19’s early phases
In normal conditions, the body produces cytokines into the circulation whenever the immune system recognizes an infection or inflammation. Cytokines are proteins, peptides and glycoproteins that are released into the site by particular immune cells that mediate and control immunity, inflammation, and hematopoiesis and that are communicated to the white blood cells that are attacking viruses or cells. The cytokines dispersed when the infected or injured cell was killed and the cells were removed as trash.
Since cytokines play a key part in combating disease infections, it might be a poor idea to reduce them as a prevention strategy or at an early stage of infection. Many authorities warn against utilizing cannabis agents early on in their sickness by suppressing immunological responses to cannabis and particular cannabinoids like CBD or THC that you can find on Greenpassion.ch
The risk of developing a disease or staying infectious is greater for patients with weaker immune systems than for those with COVID-19. There are various reasons why a person might be immunocompromised or have a weak immune system, including a soldier organ, blood, or bone marrow transplant. Nevertheless, some high-CBD extractors can prevent access to viral cells and disseminate the enzymes 2 (ACE 2), a receptor in the lung tissue oral and nasal mucosa used for SARS-CoV-2 entrance into human hosts by reducing angiotensin-converting levels. As these findings are only obtained from in vitro investigations, they are not definitive and require a broad validation and a subsequent clinical trial.
Studies that test for human patients with CBD and cannabis
No results have been obtained to date by any of the four. In addition, the good outcome would not be assured that big agencies such as The FDA in the United States or the EU European Medicines Agency would be persuaded by these tests to approve therapies for their people. Studies at other sites and with more patients would be required. It is hard to determine whether cannabis offers effective treatment until studies in which reasonably significant numbers of human patients are complete.
Is the usage of cannabis to treat COVID-19 correct?
No, still not. No. Although the idea makes sense and the first findings favorable, it is far too early to declare definitively, that the cause or symptoms of the disease and if they are more competitive medicines are successful to combat cannabis or its components. In the absence of further studies, the preliminary outcomes in cell culture model diseases or animal models cannot be expected to be effective in human patients.
It would probably take at least six, if not a year to reach the end-stage clinical trials and the market for medicinal products from top firms. The businesses now researching COVID-19 treatments and diagnostics benefit from increasing financing opportunities and a sophisticated FDA approval procedure for medicines that might be beneficial for the treatment of COVID-19.
Therefore any COVID-19 approval might make it more probable, even after the pandemic is over, that similar medications be authorized for a broader group of diseases. This possible legalization would not only help those enterprises but also the broader sector, in which CBD is recognized for its valuable and even vital medical characteristics. In addition, the statements about what cannabis can and cannot cure must always be evidence-based to promote this trend and enhance the faith of consumers and medical practitioners.
CBD Oil helps reduce lung damage
New research found that one of the non-psychoactive cannabinoids in cannabis, CBD, decreases lung damage caused by cytokine storms produced by COVID-19 by increasing levels of a natural peptide. In the authors’ ARDS model, blood levels of apelin, an essential regulator in lowering blood pressure and inflammation, decreased near to zero and rose 20 times with CBD. When blood pressure rises, for example, apelin levels should rise to aid in pressure reduction. Apelin should accomplish the same thing to help normalize lung inflammation and the breathing problems associated with ARDS. The scientists emphasize that they do not yet know if the new coronavirus or CBD has a direct influence on apelin or if these are secondary effects, but they are attempting to find out.
The next stage in the research will be to better understand the relationship between CBD, apelin, and the new coronavirus, including why apelin decreases in the face of the virus and why CBD increases it.
The researchers will investigate how removing apelin affects ARDS and if CBD provides the same lung effect without apelin. The scientists add that the virus most likely inhibits something that suppresses apelin, and CBD interferes with this process, but they also doubt that the apelin-CBD interaction is the sole way the chemical acts in this and other circumstances.
Cannabis has shown a lot of promise in combating COVID-19, owing primarily to its anti-inflammatory effects. According to a new study published in the journal Aging, cannabis might dramatically improve the condition of COVID-19 patients by decreasing cytokine storms and preserving lung tissue from inflammatory damage.